克隆性血液形成的科尔奇辛和纵向动力学:LoDoCo2试验的探索性子研究
Niekbachsh Mohammadnia1, Liying Xue2, Lucas T W Vestjens1
1Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Journal of the American College of Cardiology
|September 2, 2025
概括
低剂量的胆固醇显示出降低克隆造血 (CH) 扩张的潜力,特别是在TET2突变中,这表明可以减轻心血管疾病风险. 需要进一步的研究来确认.
科学领域:
- 血液学
- 心血管医学
- 药理学
背景情况:
- 克隆造血 (CH) 是一种与年龄相关的疾病,会增加心血管事件的风险.
- 更大的CH克隆与更高的心血管风险相关.
- 炎症信号与CH克隆扩张和心血管疾病有关,但抗炎疗法的效果尚不清楚.
研究的目的:
- 在慢性冠状动脉疾病患者中研究素与安慰剂对CH克隆生长的影响.
- 评估素对炎症生物标志物的影响与时间上的CH状态有关.
主要方法:
- 一项LoDoCo2试验的探索性子研究使用了高覆盖度测序来追踪CH驱动突变和变异性等位基因的频率.
- 测量是在基线时进行的,在开始使用素后,在一年后,在研究结束时 (中位数为25.0个月的随访期).
- 一般化的线性混合模型分析了克隆动态;IL-6和hs-CRP在关键时间点进行测量.
主要成果:
- 随机分配给安慰剂每年增加了14. 9% 的CH克隆大小,而素显示出不显著的6. 3% 的增加 (P相互作用=0. 13).
- 与安慰剂相比,素显著减弱了TET2 CH (P相互作用=0. 04) 的克隆增长,并减少了非DNMT3A CH (P相互作用=0. 01) 的IL-6增加.
- 虽然整体上没有统计学意义,但菌素趋向于减少克隆扩张.
结论:
- 在这项探索性分析中,低剂量菌素与TET2CH的克隆扩张减少有关.
- 胆固醇可能抑制CH驱动突变的增殖优势,从而降低相关心血管疾病的风险.
- 需要进行前性研究来验证这些发现.
更多相关视频
05:32In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
Published on: February 16, 2024
534
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
7.2K
相关概念视频
Bone Marrow Sampling and Transplants
493
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
493
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Hematopoiesis
5.6K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.6K
Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Multipotency of Hematopoietic Stem Cells
3.3K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.3K
